-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] With the advancement of generic drug consistency evaluation, consistency evaluation has become a battle of the strong
.
However, as Guotai Junan Securities has analyzed and pointed out, for most companies, the cost pressure of consistency evaluation projects is relatively large
.
In order to ensure the healthy, sustainable and high-quality development of the biopharmaceutical industry and ensure the use of high-quality and reasonably priced drugs for the masses, the local government also strongly supports the implementation of the consistency evaluation of generic drugs, encourages enterprises to improve the quality of research and development, and strengthen the research and development of new drugs
.
For example, according to recent news, Nantong Lianya Pharmaceutical, Jiangsu Wangao Pharmaceutical, and Jiangsu Chenpai Pharmaceutical have a total of 7 generic drugs that have passed the consistency evaluation, and 4 of them have received funding of 5 million yuan
.
Among them, the sarpogrelate hydrochloride tablets of Jiangsu Wangao Pharmaceutical passed the consistency evaluation
.
This product has anti-platelet aggregation and vasoconstriction effects.
It can be used to improve ischemic symptoms such as ulcers, pain and coldness caused by chronic arterial occlusive disease.
It is a cardiovascular and cerebrovascular drug.
The original research company is Japan Tanabe Mitsubishi Pharmaceutical Co.
, Ltd.
China approved the import of the tablet in 1998, and the patent of the drug expired at the end of April 2006
.
Previously, only Hongri Pharmaceutical in China passed the consistency evaluation
.
Jiangsu Wangao Pharmaceutical is the second domestic manufacturer of this variety to pass the consistency evaluation
.
The indications of voglibose dispersible tablets of Jiangsu Chenpai Pharmaceutical are to improve postprandial hyperglycemia in diabetes
.
According to the data, in China, the approved preparations of voglibose include voglibose tablets/dispersible tablets/chewable tablets, voglibose capsules,
etc.
Among them, tablets account for more than 90% and are the main dosage form
.
In 2020, the sales volume of voglibose in public hospitals in key provinces and cities in China will be about 124 million yuan
.
In terms of consistency evaluation, in November 2021, the voglibose tablets of Suzhou Sinochem Pharmaceutical Industry passed the consistency evaluation, the first in China
.
Jiangsu Chenpai Pharmaceutical Co.
, Ltd.
is the second domestic company that has passed the evaluation of this product
.
According to the policy requirements, "three over-evaluation" has become a threshold: if more than three manufacturers of the same variety of drugs have passed the consistency evaluation, the varieties that have not passed the consistency evaluation will no longer be selected for centralized drug procurement
.
This policy has already been implemented in many places, including Jiangxi, Jiangsu, Heilongjiang and other places, and even suspended the eligibility for online purchase of many products that have not passed the consistency evaluation
.
The industry generally believes that under the background of normalization of centralized procurement, it has become very critical for pharmaceutical companies to accelerate the competition for the top three varieties to pass the consistency evaluation
.
It is understood that since the above-mentioned two pharmaceutical companies are the second generic drugs in China to pass the consistency evaluation, they have also received funding of up to 1.
5 million yuan respectively
.
It is reported that the Nantong Municipal Market Supervision Bureau has always regarded the overall promotion of enterprises to carry out generic drug consistency evaluation as an important starting point for promoting the development, transformation and upgrading of the biopharmaceutical industry in combination with the development status of the city's biopharmaceutical industry
.
Up to now, Nantong Market Supervision Bureau has promoted 23 varieties (27 product specifications) of 7 biopharmaceutical enterprises to pass or be deemed to have passed the consistency evaluation, and cooperated with the Municipal Finance Bureau to guide 6 enterprises to apply for a subsidy of 17.
9 million yuan
.
In the future, the city's market supervision bureau will base itself on its functional advantages, strengthen scientific guidance, deepen innovation-driven development, and advance the service industry, further guide and promote the healthy, sustainable and high-quality development of Nantong's biopharmaceutical industry, and ensure that people use it with high quality and reasonable prices.
of medicines
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
However, as Guotai Junan Securities has analyzed and pointed out, for most companies, the cost pressure of consistency evaluation projects is relatively large
.
In order to ensure the healthy, sustainable and high-quality development of the biopharmaceutical industry and ensure the use of high-quality and reasonably priced drugs for the masses, the local government also strongly supports the implementation of the consistency evaluation of generic drugs, encourages enterprises to improve the quality of research and development, and strengthen the research and development of new drugs
.
For example, according to recent news, Nantong Lianya Pharmaceutical, Jiangsu Wangao Pharmaceutical, and Jiangsu Chenpai Pharmaceutical have a total of 7 generic drugs that have passed the consistency evaluation, and 4 of them have received funding of 5 million yuan
.
Among them, the sarpogrelate hydrochloride tablets of Jiangsu Wangao Pharmaceutical passed the consistency evaluation
.
This product has anti-platelet aggregation and vasoconstriction effects.
It can be used to improve ischemic symptoms such as ulcers, pain and coldness caused by chronic arterial occlusive disease.
It is a cardiovascular and cerebrovascular drug.
The original research company is Japan Tanabe Mitsubishi Pharmaceutical Co.
, Ltd.
China approved the import of the tablet in 1998, and the patent of the drug expired at the end of April 2006
.
Previously, only Hongri Pharmaceutical in China passed the consistency evaluation
.
Jiangsu Wangao Pharmaceutical is the second domestic manufacturer of this variety to pass the consistency evaluation
.
The indications of voglibose dispersible tablets of Jiangsu Chenpai Pharmaceutical are to improve postprandial hyperglycemia in diabetes
.
According to the data, in China, the approved preparations of voglibose include voglibose tablets/dispersible tablets/chewable tablets, voglibose capsules,
etc.
Among them, tablets account for more than 90% and are the main dosage form
.
In 2020, the sales volume of voglibose in public hospitals in key provinces and cities in China will be about 124 million yuan
.
In terms of consistency evaluation, in November 2021, the voglibose tablets of Suzhou Sinochem Pharmaceutical Industry passed the consistency evaluation, the first in China
.
Jiangsu Chenpai Pharmaceutical Co.
, Ltd.
is the second domestic company that has passed the evaluation of this product
.
According to the policy requirements, "three over-evaluation" has become a threshold: if more than three manufacturers of the same variety of drugs have passed the consistency evaluation, the varieties that have not passed the consistency evaluation will no longer be selected for centralized drug procurement
.
This policy has already been implemented in many places, including Jiangxi, Jiangsu, Heilongjiang and other places, and even suspended the eligibility for online purchase of many products that have not passed the consistency evaluation
.
The industry generally believes that under the background of normalization of centralized procurement, it has become very critical for pharmaceutical companies to accelerate the competition for the top three varieties to pass the consistency evaluation
.
It is understood that since the above-mentioned two pharmaceutical companies are the second generic drugs in China to pass the consistency evaluation, they have also received funding of up to 1.
5 million yuan respectively
.
It is reported that the Nantong Municipal Market Supervision Bureau has always regarded the overall promotion of enterprises to carry out generic drug consistency evaluation as an important starting point for promoting the development, transformation and upgrading of the biopharmaceutical industry in combination with the development status of the city's biopharmaceutical industry
.
Up to now, Nantong Market Supervision Bureau has promoted 23 varieties (27 product specifications) of 7 biopharmaceutical enterprises to pass or be deemed to have passed the consistency evaluation, and cooperated with the Municipal Finance Bureau to guide 6 enterprises to apply for a subsidy of 17.
9 million yuan
.
In the future, the city's market supervision bureau will base itself on its functional advantages, strengthen scientific guidance, deepen innovation-driven development, and advance the service industry, further guide and promote the healthy, sustainable and high-quality development of Nantong's biopharmaceutical industry, and ensure that people use it with high quality and reasonable prices.
of medicines
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
